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It is widely accepted that for exposure-based therapies to be effective feareliciting stimuli must be presented continuously until there is a marked decrease
in the client's anxiety (e.g., Eysenck, 1979; Foa & Kozak, 1986). However, an
emerging body of research (cf. Seim, Waller, & Spates, 2010) suggests that a
massed series of very brief exposures (< 150 sec) may be effective in the
extinction of fear responses. The present study was designed to compare the
efficacy and acceptability of two one-session treatments for animal phobias: one
that utilized continuous, uninterrupted periods of exposure to a feared animal
(Prolonged Exposures) and the other that utilized a massed series of brief (5-120
sec) exposure trials (Dosed Exposures). 24 adults (7 males, 17 females) between
the ages of 18 and 57 years (M = 23.6) participated in this study. Each individual
met DSM-IV criteria for a diagnosis of snake phobia or spider phobia.
Participants were randomly assigned to one of two the two interventions. Both
treatments required participants to gradually enter a room, approach, and
eventually hold a live ball python or tarantula. Results from mixed model
(between x within subjects) analyses of variance showed that the Dosed Exposure

treatment performed equally well to Prolonged Exposures at decreasing
behavioral avoidance, feelings of anxiety, perceptions of threat, and phobiaspecific cognitions from pre-treatment to post-treatment, and these gains were
maintained at one-week follow-up. Although participants receiving Prolonged
Exposures reported lower ratings of within-session anxiety, participants in the
Dosed Exposure group had lower rates of treatment dropout, better compliance
with procedures, and fewer safety-seeking behaviors during the treatment. These
findings suggest that, contrary to popular belief, brief exposure trials can be
effective in the extinction of phobic responses under certain conditions.
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CHAPTER I
INTRODUCTION
It is commonly assumed that in order for exposure therapies to be effective feareliciting stimuli must be presented continuously until there is a marked decrease in the
client's anxiety. However, there are only a small number of studies to support this claim,
and many of these studies carry significant methodological shortcomings. Instead, an
emerging body of research suggests that a massed series of very brief exposure trials
(<150 s) can be effective in the extinction of fear responses. This method of exposure,
known as dosed exposure therapy, has been shown to be an effective treatment for PTSD
(Renfrey & Spates, 1994), public speaking anxiety (Seim, Waller, & Spates, 2010),
injection phobia (Seim, Willerick, Gaynor, & Spates, 2008), and animal phobias (Seim &
Spates, 2009). The present study was designed to directly compare the efficacy and
acceptability of dosed exposure therapy and prolonged exposure in the treatment of
specific animal phobias.
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CHAPTER II
LITERATURE REVIEW
One of the most thoroughly studied psychotherapeutic techniques is exposure
therapy (Richard & Lauterbach, 2007). Researchers and practitioners from experiential
(Wolfe & Sigl, 1998), behavioral (Eifert & Forsyth, 2005), and cognitive-behavioral
(Beck, Emery, & Greenberg, 2005) theoretical orientations have all advocated for its use,
and hundreds of studies have been devoted to investigating the proper implementation of
this technique and the parameters which make it effective. One parameter of exposure
therapy which is rarely investigated, however, is the length of each exposure trial. It is
often assumed that exposures must be delivered in long, uninterrupted sessions in order to
be effective (Eysenck & Kelley, 1987; Foa & Kozak, 1986). This belief is so widespread
that the necessity of prolonged exposures is sometimes considered a fundamental axiom
of proper exposure therapy.
While decades of translational research and treatment outcome studies have
shown that prolonged contact with fear-evoking stimuli (delivered either imaginally or in
vivo) presented in a safe, well-controlled environment is effective at reducing anxiety
(Richard et al., 2007), there are some downsides to this method. Traditional exposures whether using in vivo, imaginal, or analog stimuli - often cause the patient to experience
significant distress during the treatment (Pitman, Orr, Altman, & Longpre, 1996). This
distress makes the exposure therapy difficult to undergo, and it often causes patients to
engage in avoidant and safety-seeking behaviors (i.e., "safety behaviors") which dilute
the impact of the intervention (Powers, Smits, & Telch, 2004; Wells, Clark, Salkovskis,
Ludgate, Hackmann, & Gelder, 1995). In addition, the fear elicited by the intervention
2

makes some patients unwilling to participate in the treatment in the first place. To get
around this, some have suggested only telling patients certain aspects of the treatment at a
time (e.g., Ost, 1997, p. 230); however, this option may only be possible in some cases.
Finally, the protracted aversive arousal incurred by traditional exposure treatments may
lead to client dropout. For example, in their research on exposure therapy for PTSD,
Zayfert and colleagues found that up to 40% of patients drop out of therapy due to
distress of the treatment or the fear of commencing the treatment (Zayfert & Black,
2000), and even therapists who are trained in exposure therapy are often reluctant to use
it out of fear of patient dropout (Becker, Zayfert, & Anderson, 2004). Despite these
quandaries, prolonged contacted with feared stimuli is often considered a necessary evil,
and some have argued that brief exposure durations may only serve to exacerbate the
client's anxiety, not reduce it (Eysenck et al., 1997). To understand this perspective, an
abbreviated history of exposure-based therapies is warranted.
Development of Prolonged Exposure Therapies
Though fear-confrontation exercises have been used for over a hundred years and
formal exposure-based procedures have been used since the early 20th century (Barlow,
2002), modern experimentation on treatments for anxiety disorders largely began with the
technique of systematic desensitization, developed by Wolpe in the 1950s (Wolpe, 1958).
Inspired by the experimental work of Pavlov (1927) and the theoretical analyses of Hull
(see Eelen & Vervliet, 2006) and Jacobson (1938), systematic desensitization was
originally believed to work as a counterconditioning procedure which lessened a patient's
likelihood of anxious responding by having them engage in a behavior that is
incompatible with anxiety (i.e., relaxation) while they imagined a series of fearful objects
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and scenarios presented in a graduated fashion (Head & Gross, 2003). The welldelineated protocol of Wolpe made systematic desensitization a technique that was not
only easily taught to and replicated by other therapists, but amenable to scientific
dissection (Rachman, 1967). Soon after its introduction, psychologists and psychiatrists
in Africa, Europe, and the Americas were conducting dismantling studies and component
analyses to investigate the mechanism through which systematic desensitization worked
and the parameters which made it most effective. It was eventually found that in vivo
exposures were more effective than imaginal exposures (Bandura, Blanchard, & Ritter,
1969; Ultee, Griffioen, & Schellenkens, 1982), that the relaxation component of the
technique was unnecessary (Rachman, 1968), and that therapists need not wait for their
patient's subjective anxiety to decrease before higher items on the feared stimulus
hierarchy are presented (Yuksel, Marks, Ramm, & Ghosh, 1984). Thus, variations of the
techniques known as "in vivo graded exposure" and "flooding" were developed.
In addition to this research, studies were conducted to investigate the optimal
duration of the exposure trials used in anxiety treatments. Miller and Levis (1971)
assigned four adolescent females with non-clinical snake fears to a no-treatment control
group or exposure sessions of 15 min, 30 min, or 45 min. The results indicated that the
30 min and the 45 min exposure treatments were more effective than both the 15 min
exposure session and the control condition, as measured by the participants' ability to
approach a snake after treatment. In addition to significant methodological shortcomings,
such as the participants displaying unequal levels of fear at baseline and the betweengroup differences in total duration time, the external validity of this study is highly
suspect, as only one participant was placed in each group.
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A larger study was conducted by Stern and Marks (1973) to compare the effects
of four treatments on 16 participants presenting with agoraphobia and other travel-related
phobias. Each participant received two treatments involving imaginal exposures: one
consisting of an 80 min imaginal exposure trial, and another consisting of eight 10 min
exposure trials separated by a five min break. Each participant also received two
treatments involving in vivo exposures: one consisting of a 120 min exposure trial, and
another consisting of four 30 min exposures separated by 30 min rest periods. The
participants received all four treatments over the course of two weeks, and the order of
the treatments was randomized using a Latin-square design to control for carryover
effects. The outcome data indicated that imaginal exposures were ineffective at reducing
agoraphobic anxiety, and, while both in vivo exposure treatments helped, the 120 min
session produced greater results.
Using this same temporal scheme, Rabavilas, Boulougouris, and Stefanis (1976)
investigated the effects of brief and prolonged exposures in the treatment of obsessivecompulsive disorder. Like Stern and Marks (1973), the authors found that imaginal
exposures were ineffective at reducing anxiety, and that prolonged in vivo exposures
produced greater results than brief in vivo exposures, as measured by reductions in both
targeted and overall obsessions.
To compare treatments for public speaking anxiety, Chaplin and Levine (1981)
randomly assigned 48 college students to receive either one 50 min session or two 25 min
sessions of imaginal exposure. Participants in the prolonged condition reported an
increase in anxiety during the first 25 min of exposure, followed by a steady decrease in
anxiety, thereafter. Conversely, participants receiving the brief exposures reported an
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increase in anxiety during the first exposure trial, a return to baseline during the 10 min
break, and another steady increase in anxiety during the second exposure trial. The
authors suggested that "interrupting" prolonged exposure therapy impairs habituation,
and is thus contraindicated.
A final study, conducted by Marshall (1985), investigated the effects of exposures
presented until any slight decrement in anxiety was achieved ("Brief 1" exposures),
exposures presented until a 75% drop in anxiety was achieved ("Brief 2"), exposures
presented until a 90% drop in anxiety was achieved ("Standard"), and exposures
presented for well after a complete absence of anxiety was achieved ("Prolonged").
Results indicated that both standard and prolonged exposures were effective at reducing
acrophobic symptoms, while brief exposures produced no significant improvements.
The results of these five studies led to the conclusion that prolonged exposures
were necessary in the treatment of anxiety. However, a significant limitation existed
across all studies, in that the use of the term "brief exposures was relative to the
comparison groups. In the study by Marshall (1985), the definition of "brief exposures
was not defined by time, but by idiographic changes in each participant's subjective
anxiety. And, in the studies of Miller et al. (1971), Stern et al. (1973), Rabavilas et al.
(1976), and Chaplin et al. (1981), the durations of the "brief exposures were between 10
and 30 minutes long. This falls in stark contrast to the original Pavlovian model of
extinction as well as research by Baum (1969) which suggests that CS presentations
lasting over three minutes in length are no more effective than presentations lasting only
three minutes.
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Evidence for Intermittent Exposures
A small and often unrecognized body of research provides some support that brief
exposures can be effective in the reduction of anxiety. Early research on conditioned fear
responses in animals demonstrated that exposures lasting no longer than 15s could
effectively extinguish avoidant behaviors (Black, 1958; Nelson, 1966), research by
Berman and Katsev (1972) showed that forty 5 s exposures were more effective than one
200 s exposure, and other research has demonstrated that, regardless of the number of
extinction trials, total exposure time is the critical variable (Schiff, Smith, & Prochaska,
1972; Shearman, 1970), even when exposures range between 1 min and 24 min in length
(Martasian, Smith, Neill, & Rieg, 1992).
Research on human anxiety has demonstrated promise for brief exposures, as
well. For example, dismantling studies (e.g., Rachman, 1968) indicated that the core
feature of the systematic desensitization technique was its use of very brief trials of
imaginal exposure, usually lasting between five and seven seconds (Head et al., 2003).
The reliable results of this treatment kept it the gold standard for well over a decade after
its introduction. Indeed, the first study published on "flooding" (i.e., prolonged
exposure), found that systematic desensitization produced more favorable results
(Rachman, 1966).
In their comparison of brief versus prolonged exposures, Mathews and Shaw
(1973) subjected 40 adults with spider phobias to either one 48 min trial or six 8 min
trials of imaginal exposure. The results indicated that both brief and prolonged exposures
were immediately effective at reducing participants' subjective anxiety and there were no
differences in overt behavioral avoidance at one-month follow-up.
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Grey, Rachman, and Sartory (1981) randomly assigned 28 participants with
various animal phobias to treatments consisting of either one 20 min exposure to a feared
animal or ten 2 min exposures. The results showed no significant differences between
the treatments regarding subjective reports and behavioral indices of anxiety. However,
the authors stated that participants in the two groups differed in heart rates at baseline,
and this may have affected their anxiety and responsiveness to the treatment. Thus, an
unambiguous interpretation of the results was not possible.
In the late 1980s, a multi-component technique known as Eye Movement
Desensitization and Reprocessing (EMDR) (Shapiro, 1989) was developed for the
treatment of PTSD and other anxiety disorders. EMDR required patients to imagine a
traumatic or fear-eliciting event for approximately 15 s while engaging in rhythmic
lateral eye movements (Cusack & Spates, 1999). These imaginal exposures were
presented several times during the course of each therapy session, and the exposures were
separated by brief inter-trial intervals when the patient was taught to reflect on his or her
affective state and replace negative cognitions with more adaptive thoughts. EMDR was
roundly dismissed by many cognitive-behavioral therapists, largely because of its weak
theoretical basis, its lack of ties to basic research, and its promotion by some as a
psychological panacea. However, in spite of these limitations, strong empirical evidence
supported the efficacy of this approach (Spates, Koch, Cusack, Pagoto, & Waller, 2008;
Wilson, Becker, & Tinker, 1995). A series of dismantling studies was undertaken, and it
was eventually discovered that both the saccadic eye movements (Renfrey et al., 1994)
and the cognitive exercises (Cusack et al., 1999) were unnecessary components. Thus, it
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was concluded that the mechanism behind EMDR was its use of a series of brief
exposures (Spates & Koch, 2003).
Harkening to Wolpe's original emphasis on what he referred to as brief "doses" of
exposure (Wolpe, 1958, p. xi), Spates and colleagues began a series of experiments on
what was termed "dosed exposure" therapy (Spates & Seim, 2005). In line with the
Pavlovian model of exposure, the dosed exposure technique utilizes a series of very brief
exposure trials (< 150 s) which are separated by brief inter-trial intervals (i.e., the
exposures are massed).
Waller (2004) investigated the efficacy of this approach in the treatment of public
speaking anxiety. Using a multiple baselines across subjects design, three participants
were asked to deliver an impromptu speech in front of a small audience by speaking for
30 s, taking a 30 s pause, and then speaking again for 30 s until they had a significant
reduction in their subjective anxiety. Pre- to post-treatment comparisons using a
behavioral avoidance test which required the participants to deliver a 3 to 10 min speech
indicated that anxiety was reduced across subjective, behavioral, and physiological
measures. When compared to three participants who received a similar treatment using
prolonged exposures, the dosed exposure treatment was shown to produce less withinsession anxiety and more consistent reductions in autonomic arousal. While the small
number of participants limits the generalizability of its results, this study does provide
some evidence for the use of in vivo exposures presented in a dosed fashion.
Using a similar stimulus dosing procedure, Seim, Willerick, Gaynor, and Spates
(2008) treated a woman with an 18-year history of severe injection phobia. By
presenting still images, video displays, drops of fake blood, and actual needles and
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syringes in a massed series of exposure trials lasting between five and 120 seconds, the
participant's subjective anxiety and phobic symptoms were significantly reduced in one
session, and she was eventually able to receive a series of finger pricks, vaccinations, and
a booster shot. In addition, the participant's lifelong history of fear-induced vasovagal
syncope (fainting reflex) was effectively eliminated, as measured by one-week and oneyear follow-up assessments.
Larger N studies have also been conducted. Rubin, Spates, Johnson, and Jouppi
(2009) compared the effects of four forms of imaginal exposure in the reduction of public
speaking anxiety. 39 participants were randomly assigned to one of four conditions. In
the first condition, the participants received 2.5 minutes of exposure to an imagined
public speaking scene. In the second condition, participants received ten 15 s trials of
exposures separated by 30 s inter-trial intervals. The third and fourth conditions were
identical to the second condition, except they supplanted the empty inter-trial intervals
with 30 s periods involving positive or negative imagery, respectively. Results indicated
that the second and third conditions produced less aversive arousal and more rapid
reductions in anxiety than the first and fourth conditions.
Finally, a study by Seim and Spates (2009) examined the efficacy of in vivo
dosed exposures in the treatment of snake and spider phobias. Ten participants meeting
DSM-IV criteria for specific animal phobias were each treated in a single 3 lA session
involving direct contact with a python or a tarantula. The sessions required participants
to undertake 17 behavioral tasks to learn to approach the animal and hold it in their
hands. Each task consisted of five to six exposure trials between 5 and 120 s in duration,
and each trial concluded with a 45 s break outside of the therapy room. Data collected
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post-treatment and during one-week and three-month follow-ups indicated that the
treatment resulted in clinically significant improvements in behavioral avoidance,
autonomic arousal, subjective anxiety, and cognitions of threat.
Summary
It is clear that there are decades of evidence demonstrating that prolonged
exposure therapies are effective treatments for anxiety. However, the aversive nature of
these interventions makes many unwilling to undergo or complete treatment. Despite
claims that prolonged, continuous contact with feared stimuli is a necessary parameter of
exposure therapy, there are only a handful of studies to support this notion, and each of
these studies carry methodological shortcomings, particularly in regards to their use of
the term "brief exposures. A small but growing body of research suggests that very
brief exposures separated by brief inter-trial intervals ("dosed" exposures) can effectively
eliminate fear responses. However, treatment outcome research directly comparing
dosed exposures with traditional prolonged exposures has yet to be conducted.
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CHAPTER III
PROPOSED STUDY
This study directly compared two empirically supported exposure-based therapies
for specific animal phobias: dosed exposure therapy and prolonged exposure therapy.
Dosed Exposure Therapy
The dosed exposure treatment was based on the intervention used by Seim et al.
(2009). This treatment has been shown to be effective at eliminating snake and spider
phobias. It incorporated four key parameters:
Brief, Incrementing Exposure Trials
Instead of incorporating continuous contact with feared stimuli, the dosed
exposure therapy consisted of a series of very brief exposure trials. Each gradation of the
treatment began with a 5 s exposure, and the length of subsequent exposures gradually
increased to 60 or 120 s. No exposure trial lasted longer than two minutes.Brief Inter-trial Intervals
Each exposure trial was separated by only a 45 s break period, where the
participant was completely removed from the targeted feared stimuli. Research using
both animals (Cain, Blouin, & Barad, 2003; Pereya, Portino, & Maldonado, 2000) and
humans (Rowe & Craske, 1998) has shown that frequent presentations of exposures (i.e.,
massed treatments) are better at fostering extinction than exposures with longer inter-trial
intervals (i.e., spaced treatments).
Facilitation of Approach Behaviors
Instead of having the feared stimuli (held by the therapist) gradually approach the
participant, this treatment required each participant to physically approach the animal.
12

Research has demonstrated that active participation during treatment may be more
effective than passive participation, even during imaginal exposures (Rentz, Powers,
Smits, Cougle, & Telch, 2003). This comports with many mindfulness-based treatments,
which encourage clients to act towards a valued goal in spite of their anxiety (e.g., Hayes,
Strosahl, & Wilson, 1999; Morita, 1998), and with self-efficacy theory (Bandura, 1977),
which suggests that anxiety treatment outcomes are not dependent on mere contact with
feared stimuli but on the client's sense of control over their behaviors and their ability to
keep in contact with the feared stimulus.
Response Prevention
To extinguish the negative reinforcement of fear responses, participants were
instructed to keep in contact with the feared stimuli during the entirety of each exposure
trial. In addition, participants were discouraged from engaging in safety behaviors and
mental distraction techniques, as these are likely to impair the treatment.
Prolonged Exposure Therapy
The prolonged exposure treatment used in this study was similar to the onesession in vivo exposure treatment developed by Ost (1989, 1997). This treatment can
usually be completed in three hours, and long-term follow-up results are favorable
(Zlomke & Davis, 2008). Unlike Ost's treatment, the prolonged exposure treatment used
in this study eliminated cognitive exercises, such as explicitly challenging fearful
thoughts with behavioral experiments. Research by Koch, Spates, and Himle (2004)
showed that these cognitive exercises are not essential to the treatment, and the use of
cognitive exercises in the present study would have presented a potential confound
regarding the efficacy and acceptability of the treatments. Like the dosed exposure
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treatment, the prolonged exposure treatment facilitated active participation during the
exposure and prevented escape and avoidant responses from participants. However, this
treatment did not utilize brief exposure trials and inter-trial intervals.

14

CHAPTER IV
HYPOTHESES
The research question addressed by this study was whether dosed exposure
therapy for the treatment of animal phobias is as effective as prolonged exposure therapy.
This question was examined through the empirical analysis of four hypotheses:
1. Dosed exposure therapy will produce equivalent reductions in anxiety as
prolonged exposure therapy, as measured by behavioral tests, subjective ratings,
and standardized self-report measures.
2. The average total treatment time for dosed exposure therapy will be within one
hour of the average total treatment time for prolonged exposure therapy.
3. Participants will be less likely to engage in safety behaviors and be less likely to
exhibit behavioral indices of distress during the dosed exposure treatment than
during the prolonged exposure treatment.
4. Participants will find the dosed exposure treatment less aversive and more
acceptable than the prolonged exposure treatment, as measured by physiological
and paper-and-pencil measures.

15

CHAPTER V
METHODS
Participants
Participants were recruited through speeches delivered to college classes and
through flyers posted around the campus of Western Michigan University (see
Appendices C-E). Fifty-eight males and females contacted the researchers to learn more
about the study. After speaking with a member of the research team, 27 of these
individuals stated that a fear of snakes or spiders affected their lives in a significant way
and decided to schedule an appointment to participate in the study. Phobia diagnoses
were made using the specific phobia interview from the Anxiety Disorders Interview
Schedule (ADIS-IV; Brown, Di Nardo, & Barlow, 1994), a structured clinical interview
based on the DSM-IV (American Psychiatric Association, 2000). The ADIS-IV has been
demonstrated to be a valid measure of specific phobia with high test-retest reliability
(Brown, Di Nardo, Lehman, & Campbell, 2001), and it has been used as an inclusionary
measure in many other treatment outcome studies on animal phobias (e.g., Koch et al.,
2004; Ost, Ferebee, & Furmark 1997). Two participants did not meet diagnostic criteria,
and another participant completed all nine steps of the BAT-1 assessment (see below).
Therefore, these participants did not qualify for either treatment.
The final sample consisted of 24 adults (7 males, 17 females) presenting with
significant fears of snakes (n = 10) and spiders (n =14). Eighteen participants identified
as Caucasian, two as African American, one as Hispanic/Latino, and three as multiracial.
The age range of participants was between 18 and 57 years, with a mean age of 23.6
years (SD = 9.79).
16

Each participant had a long history of phobic symptoms (2-47 years) which began
around age 7, on average. Five participants reported their symptoms were due to firsthand negative experiences with the feared animal, four participants stated their symptoms
were due to vicarious conditioning (e.g., witnessing their mother's reaction to spiders),
and fifteen participants did not know the origin of their phobias.
Twenty-two participants meet full DSM-IV criteria for a diagnosis of a specific
animal phobia, while two participants met all criteria with the exception of Criterion E
(i.e., the fear significantly interferes in the person's life or the person has marked distress
about having the phobia). In addition to this measure, all participants included in the
study were unable to stand closer than three feet from a glass cage containing the feared
animal. Other inclusionary criteria were that all participants were over the age of 18 and
all had the ability to provide informed consent. Exclusionary criteria included a selfreported history of heart or ambulatory problems, a commencement or change in
psychotropic medications during the past month, or visible or recognizable signs of
intoxication from a substance at the time of the experimental session(s).
Two standardized instruments were used to measure general symptoms of anxiety
at pre-treatment: the Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, &
McNally, 1986) and the State-Trait Anxiety Inventory (STAI; Spielberger, Gorsuch,
Lushene, Vagg, & Jacobs, 1983). The ASI is a 16-item self-report measure designed to
assess for participants' general sensitivity to internal sensations and their likelihood of
evaluating anxious arousal as threatening. The average ASI score amongst participants
was 24.8 (SD = 9.0). This was slightly higher than averages for other individuals with
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specific phobia (ASI = 20), as reported by Rapee and colleagues (1992). There was no
significant difference in ASI scores between treatment groups.
The STAI consists of two 20-item subscales which are designed to measure
participants' current feelings of anxiety as well as the general amount of anxiety they
experience day to day. Both measures have been shown to have good reliability and
validity. The mean score on the State Anxiety subscale was 46.4 (SD = 12.7), which is
higher than average scores for this age group and similar to those evoked during
conditions when one has to take a difficult exam (Spielberger et al., 1983). The mean
score on the Trait Anxiety subscale was 39.3 (SD =11.6). This score is within one
standard deviation of average scores on this subscale (Spielberger et al., 1983). There
was no significant difference in STAI scores between groups.
Design
This study employed a treatment-comparison strategy (Kazdin, 2003) and utilized
a between-groups design. This design was selected because it allowed for direct
comparisons to be made regarding the efficacy and acceptability of two treatments,
prolonged exposure and dosed exposure. Each participant was treated separately in this
experiment, and the participants had no contact with each other during the experimental
sessions.
The study consisted of five periods: a Pre-Treatment baseline session, a Treatment
session, a Post-Treatment session, a One-Week Follow-Up session, and a Three-Month
Follow-Up session. During the pre-treatment baseline session, participants were given a
behavioral avoidance test which measured how close they were willing to stand near a
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feared animal (see BAT-1 below). Participants were randomly assigned to treatments
based on their scores on this test using a stratified random sampling procedure.
Setting
Three rooms were used in this study. The diagnostic interview and all paper-andpencil measures were completed in one of the small therapy rooms in the 2500 suite of
Wood Hall on the campus of Western Michigan University. The treatment session was
conducted in 2521 Wood Hall, a windowless room measuring 15' long. A glass cage
containing a snake or a spider was placed at the end of the room diagonally opposite from
the entrance. The snake used was a ball python, a venomless animal known for being a
docile pet. The spider was a Chilean rose-haired tarantula. Both animals were housed
and cared for according to the standards of the Western Michigan University Institutional
Animal Care and Use Committee (IACUC). Six lines were placed on the floor measuring
15, 12, 9, 6, 3, and 0 feet away from the cage. In addition, a 4' x 6' area was sectioned
off directly outside of the exposure room. This area was used for the break periods
between exposure trials.
Dependent Variables
Behavioral Avoidance
The primary outcome variable measured in this experiment was each participant's
avoidance behavior with respect to the feared animal. This was measured using two
Behavioral Avoidance Tests (BATs). BATs are commonly used in phobia treatment
studies (e.g., Koch et al., 2004; Powers et al., 2004; Waller et al., 2004). While selfreport measures allow researchers to measure participants' beliefs about their fears, BATs
are more valid measures of actual phobic behaviors. The first BAT (hereafter referred to
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as BAT-1) measured how close each participant was able to be near an open (lidless)
cage containing the snake or the spider. BAT-1 consisted of nine steps:
1. Standing outside of the room containing the animal
2. Standing 12 feet away from the animal
3. Standing nine feet away from the animal
4. Standing six feet away from the animal
5. Standing three feet away from the animal
6. Standing directly in front of the animal's cage
7. Placing one's hands on the sides of the cage
8. Placing one's hands on the rim of the cage
9. Placing one's hands on the inside glass of the cage
The second BAT (i.e., BAT-2) was based on time rather than distance. Each
participant was asked to hold the previously feared animal in their palms while the
therapist stood nine feet away from him or her. The total amount of time that the
participant was willing to hold the animal (up to two minutes) was recorded.
Heart Rate
Participants' heart rates were measured during each session of the experiment
using a mobile heart rate monitor. This monitor was attached to the participant's chest
with a nylon strap. ECG sensors from the device transmitted heart rate data to a
wristwatch worn by the therapist.
Subjective Anxiety and Threat Perception
Three measures of each participant's affective states were monitored during the
BATs and the treatment: subjective feelings of anxiety (SUDS), subjective feelings of
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danger, and subjective feelings of control in regards to the animal. Each of these
measures was based on a 101-point scale (i.e., 0 = no anxiety; 100 = the most anxiety
possible).
Self-Efficacy
Participants' beliefs in their ability to perform a behavioral task were assessed
before and after each exposure task. In accordance with the recommendations of
Williams (1996), participants were not asked to rate their willingness to perform the task
or to predict if they would complete the task. Instead, they were asked to indicate how
capable they believed they were in completing the task on a scale from zero (incapable)
to 100 (completely capable).
Phobic Symptoms
Each participant completed an Animal Questionnaire and an Animal Fears Scale,
paper-and-pencil measures designed to measure phobic symptoms. The Animal
Questionnaire consisted of the Snake Questionnaire (Klorman, Hastings, Weerts,
Melamed, & Lang, 1974), a 30-item true or false questionnaire, or the Spider
Questionnaire (Klorman et al., 1974), a similar 31-item questionnaire. These measures
were designed to measure the distress, disgust, and avoidance participants believe they
would have in real-life situations involving snakes or spiders, respectively. Both
questionnaires have been empirically shown to be valid measures of phobic cognitions.
The Animal Fears Scale consisted of either the Snake Fears Scale or the Spider
Fears Scale, two unpublished measures of phobic cognitions. These measures were
previously used in the Seim (2009) study and were used in this study for two reasons.
First, unlike the Animal Questionnaires which require participants to answer questions as
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true or false, the Animal Fears Scales contain 5-point Likert scales, which allow
participants to not only endorse but to rate the severity of certain fears. Using this format
allows researchers to track decreases in fears which have not been fully extinguished.
For example, after receiving treatment a participant may still endorse having a fear of
spiders biting him or her but the severity of this fear may have decreased. The second
reason these scales were used was that they are designed to measure different types of
symptoms than the other measures. While the Animal Questionnaires were designed to
measure distress and disgust using very specific real-life scenarios (e.g., a spider crawling
on the ceiling over one's bed, a snake appearing on a movie screen) the Animal Fears
Scales are designed to measure more general fears which may actually be experienced
during the treatment (e.g., "Fear of holding a spider in my hands," "Fear of angering or
frightening a spider," "Fear of a snake biting me.").
Safety Behaviors and Indices of Distress
Overt safety behaviors which may be detrimental to treatment outcomes were
monitored using a checklist. The safety behaviors assessed included the following:
1. Closing Eyes - This is defined as the participant closing their eyelids for more
than five seconds during an exposure trial.
2. Covering Face - This is defined as the participant using their hand or forearm
to cover or shield their eyes, nose, or mouth for any period of time during an
exposure trial.
3. Turning Away - This is defined as the participant turning their head or body
away from the feared animal for more than five seconds during an exposure
trial.
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4. Holding Self- This is defined as the participant grabbing a part of their body
for more than five seconds during an exposure trial.
5. Holding Out Arms - This is defined as the participant extending at least one
arm towards the feared animal in any way that is not mandated by the
treatment. Extending an arm to pet or hold the feared animal will not be
considered a safety behavior.
6. Moving Backwards - This is defined as the participant moving both feet
backwards or moving their chair backwards during an exposure trial unless
requested to do so by the therapist.
7. Asking for Help - This is defined as the participant requesting the therapist to
re-model a task or to provide any physical aid that is not explicated in the
treatment protocol.
8. Asking for Reassurance - This is defined as the participant asking the
therapist to reassure their safety at any time during an exposure trial.
Any occurrences of these behaviors were recorded by the therapist after each exposure
trial along with three behavioral indices of distress: eye watering, crying, and shaking.
Treatment Acceptability
Treatment acceptability was measured using the Distress/Endorsement Validation
Scale (DEVS; Devilly, 2004), a 10-item questionnaire that indicates a participant's
satisfaction with therapy. The DEVS includes two subscales: Distress, which measures
the anxiety experienced by the participant during the treatment, and Endorsement, which
rates the participant's satisfaction with the results of the intervention and their willingness
to recommend the treatment to others. The DEVS has been used in previous phobia
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treatment outcome studies (Koch et al., 2004; Seim et al., 2009), and it has demonstrated
good reliability in discriminating participants' responses to different treatments (Devilly,
2004).
Procedures
Informed Consent
After expressing interest in the study through phone calls or emails to the Anxiety
Disorders Laboratory, participants were invited to participate in the Pre-Treatment
baseline session. Participants were given an informed consent document to read
(Appendix F). This document provided an overview of the study and detailed the
participant's right to participate or abstain from participating. It also stated that
participants have the right to withdraw from the study at any point in time without
penalty. After the participant read and signed this document, the study session began.
Pre-Treatment Session
The participant was first asked to look at the Exclusionary Criteria form
(Appendix G) and then asked if they could answer 'yes' to any of the statements listed. If
a participant indicated that he or she could answer affirmatively, the therapist would have
informed him or her that he or she was ineligible to participate in the study and a list of
nearby counseling centers would have been provided if further therapy was requested
(Appendix H). If a participant did not endorse the statements, the therapist asked him or
her complete the Demographics form (Appendix I), which solicited for basic
demographic information, comorbid fears, the history of the participant's fear, and his or
her perceived likelihood of success in treatment. After this was completed, the therapist
administered the ADIS-IV Specific Phobia Interview to determine if the participant met
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criteria for a diagnosis of specific animal phobia. If the participant met diagnostic criteria
(with the possible exception of Criterion E), the study proceeded. If the participant did
not meet criteria, the therapist would inform him or her that he or she was ineligible to
continue and a list of counseling centers would be offered.
Next, each participant completed the Anxiety Sensitivity Index and the State-Trait
Anxiety Inventory. Also, depending on the participant's fear, he or she was asked to
complete the Snake Questionnaire and the Snake Fears Scale (Appendix J) or the Spider
Questionnaire and the Spider Fears Scale (Appendix K).
After this, the therapist gave the participant the sensor-band of a mobile heart rate
monitor. The therapist instructed the participant on how to wear the monitor, and he then
left the room while the participant attached the sensor to his or her chest.
Next, the participant was escorted to a chair outside of the therapy room and
asked to sit while the therapist recorded his or her baseline heart rate and ratings of
subjective anxiety and threat perception. After these recordings were made, the therapist
opened the door to the exposure room and asked the participant to stand as close as they
could to the feared animal, as prescribed by the BAT-1 (see above).
Following this, the participant was escorted back outside of the room where his or
her heart rate and subjective ratings of anxiety and threat perception were again recorded.
Based on the results of the BAT-1, the participant was then assigned to either the Dosed
Exposure (DE) or the Prolonged Exposure (PE) conditions, and within 48 hr - if not
immediately - the treatment session commenced.
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Treatment Session
Both treatment conditions involved participants learning to approach, make
contact with, and hold a live animal. The tasks required of participants were identical
across conditions; however, the frequency, duration, and intervals between each of these
tasks differed between the two conditions. All treatment sessions were video recorded.
Dosed Exposure Condition (DE). The DE condition consisted of 17 tasks, and
each task was divided into four to six epochs. Each epoch consisted of an exposure trial
ranging from 5 to 120 s in duration and a 45 s inter-trial interval (see Appendices L &
M). The first eight tasks were equivalent to the last eight steps of the BAT-1. Each
participant's treatment began at the task coinciding with the last step he or she completed
in the BAT-1. For example, if the participant was able to stand 3' from the cage during
the BAT-1, the DE treatment began at Task #4 (the same distance).
Each task was explained to the participant and modeled by the therapist before the
participant was asked to complete it. For example, if the treatment began at Task #1, the
therapist entered the room and stood on the line marked 12' away from the cage before
the participant was asked to do the same and stand next to him. The therapist then
instructed the participant to focus on the animal during the entire exposure and avoid
looking away or thinking about other things. After 5 s, the therapist escorted the
participant back outside of the room, closed the door, asked the participant sit in the
chair, and then recorded the participant's heart rate and subjective feelings of anxiety,
danger, and control. A visual analog scale (Appendix N) was shown to the participant to
aid in the consistency of his or her subjective ratings. The therapist also noted the
occurrence of any safety behaviors or indices of distress during that exposure trial. After
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45 s passed, the therapist escorted the participant back into the room and asked them
stand on the same line for 10 s. He then took the participant outside of the room, closed
the door to the exposure room, and recorded the participant's heart rate, his or her
subjective feelings of anxiety, danger, and control, and the occurrences of safety
behaviors and indices of distress during the 10 s exposure trial. This sequence of
incrementing exposure trial durations and 45 s inter-trial intervals continue until the
participant completed the last trial of the task.
At the end of the task, the therapist then showed the participant another visual
analog scale (Appendix O) and asked him or her to rate how capable he or she believed
they would be in completing this task again on a scale from 0 to 100. The participant's
response was then recorded on the Participant Monitoring form (Appendix Q). After this,
the therapist informed the participant of the next task, he modeled the requisite behavior
to the participant, and then the first trial of that task began.
The first five tasks of the DE treatment taught the participant to enter the exposure
room and approach the caged snake or spider. The trials for each task graduated up from
5 s to 30 s. Tasks 6-8 graduated up from 5 to 60 s in duration and involved the
participant learning to place his or her hands closer and closer to the animal.
After these tasks were completed, the therapist placed the snake or spider in a
large plastic tub (30" x 24" x 18") in the middle of the exposure room. The larger space,
the smoother surface, and the lack of corners of the tub tended to make the snake and
spiders easier to handle, but also more restless. The participant was then brought back
into the room to complete Tasks 9 and 10, which required him or her to approach this tub.
Tasks 11-17 differed between DE snake and spider treatments.
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DE Snake Treatment Tasks 11-17
Task 11 - The therapist held the snake in one hand. The participant then touched
the back of the therapist's other hand as he touched the snake's back. The trials ranged
from 5 to 30 s in duration.
Task 12 - The therapist held the snake in one hand while the participant touched
the snake's back with two fingers. These trials ranged from 5 to 60 s in duration.
Task 13 - The therapist held the snake in one hand while the participant stroked
the snake's back with his or her fingers. These trials ranged from 5 to 60 s in duration.
Task 14 - The therapist gently stretched the snake's body, leaving about six
inches of the snake exposed between his two hands. The participant then placed his or
her fingertips under the snake's belly. These trials ranged from 5 to 120 s in duration.
Task 15 - The snake was again elongated and then lowered onto the participant's
upward facing palms, allowing him or her to feel the weight of the snake while the
therapist controlled the snake's head and tail. These trials ranged from 5 to 120 s in
duration.
Task 16 - The participant held the snake in his or her hands while the therapist
stood next to him or her. These trials ranged from 5 to 120 s in duration.
Task 17 - The participant held the snake in his or her hands while the therapist
stood nine feet away from him or her. This task consisted of one trial, 120 s in duration.
DE Spider Treatment Tasks 11-17
Task 11 - The participant reached into the tub and gently touched the spider's
back legs with a sheet of card stock, moving it forward. The therapist then guided the
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participant in learning how to move the spider and steer its direction using the card.
These trials ranged from 5 to 30 s in duration.
Task 12 - Using the card, the participant steered the spider into a plastic cup. The
participant then sealed the spider in the cup with the card and picked it up. These trials
ranged from 5 to 60 s in duration.
Task 13 - The participant touched the back of the therapist's hand while he
moved the spider forward using his fingers. These trials ranged from 5 to 60 s in
duration.
Task 14 - The participant reached into the tub and moved it forward by touching
its hind legs with the back of his or her fingers. These trials ranged from 5 to 120 s in
duration.
Task 15 - The participant placed the back of his or her hands on the floor of the
tub, and the therapist moved the spider onto the participant's palms. These trials ranged
from 5 to 120 s in duration.
Task 16 - The participant held the spider in his or her hands while the therapist
stood next to him or her. These trials ranged from 5 to 120 s in duration.
Task 17 - The participant held the spider in his or her hands while the therapist
stood nine feet away from him or her. This task consisted of one trial, 120 s in duration.

Prolonged Exposure Condition (PE). The PE condition proceeded in a similar
fashion to the DE condition. Each of the 17 behavioral tasks in the DE condition were
required by the PE condition, as well. However, there was no "dosing" of the exposures.
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Instead, participants were expected to remain in the room and continue with each task
until the treatment was completed.
Successful completion of a task was defined by the participant engaging in the
required behavior for at least 120 s without emitting safety behaviors or behavioral
indices of distress. After each task was successfully completed, the therapist showed the
visual analog scales to the participant and recorded his or her subjective feelings of
anxiety, danger, control, and mastery of the task. He also recorded the participant's heart
rate and any occurrences of safety behaviors and indices of distress during the task. Each
of these measures were recorded inside the exposure room.

Post-Treatment Session
Immediately after the treatment session, the BAT-1 was re-administered and the
BAT-2 was then administered. Finally, the therapist escorted the participant back to the
room where the diagnostic interview was held, and he or she re-completed the Animal
Questionnaire and the Animal Fears Scale.

One-Week Follow-Up Session
This session took place seven to 14 days after the treatment session. During this
session, the BAT-1, the BAT-2, the Animal Questionnaire, and the Animal Fears Scale
was re-administered. In addition, the DEVS was completed by the participant as a
measure of his or her satisfaction with the treatment.
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Three-Month Follow-Up Session
This session took place at least 90 days after the treatment session, and it
proceeded identically to the One-Week Follow-Up session.
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CHAPTER VI
RESULTS
Mixed model analyses of variance (between-subjects x within-subjects split-plot
ANOVA) were used to examine differences between the two treatments in regards to
behavioral avoidance, anxiety, feelings of danger, feelings of control, and phobic
cognitions across three time periods (immediately before, immediately after, and one
week following the treatment session). Mixed model ANOVAs were also used to
examine differences between the two treatments on measures of heart rate and emotional
and cognitive states over the course of the individual treatment sessions. In addition,
independent-samples t-tests and chi-square tests of independence were used to examine
differences in post-treatment scores between the groups. All tests used significance
levels of <x = .05.

Treatment Completion
Length of time to complete treatment differed between the Prolonged Exposure
(PE) and Dosed Exposure (DE) conditions. The average duration of PE for Snake phobia
was 2 hours and 32 minutes, while the average duration of DE was 3 hours and 48
minutes. Similarly, the average length of PE for Spider phobia was 3 hours and 5
minutes, whereas DE for Spider phobia averaged 3 hours and 46 minutes. Although the
DE treatments required more total session time than either PE treatment, each participant
receiving DE had a total of only 32 minutes in contact with feared stimuli. The rest of
the session time was spent sitting outside of the room or preparing for exposure tasks
(e.g., moving the animal into place). Conversely, each PE treatment session was spent
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inside of the exposure room facing the feared animal, making the time each participant
spent in contact with feared stimuli much longer (-2-3 hours).
The two treatments also differed significantly in dropout rates (x2 = 4.8,/? = .028).
While all 12 individual receiving DE successfully completed each of the 17 treatment
tasks, from first approaching the closed cage to holding the previously feared animal
while the therapist stood nine feet away, only eight (67%) of the participants receiving
PE were able to complete all tasks. Of those who were unable to complete the treatment,
one dropped out during Task 12 (capturing the spider with a card and cup), one during
Task 14 (touching the snake's belly), and two during Task 15 (spider crawling over pt's
palm; pt. supporting the weight of the snake's belly), making the average number of tasks
completed by participants receiving PE to be 16 (SD = 1.6).
Participants receiving DE also exhibited fewer difficulties complying with the
treatment protocol. An average of 10% (SD = .1) of treatment tasks during PE were
marked by hesitation from participants or attempts to negotiate with the therapist (e.g.,
"Can I just move one foot closer instead of three?"). In contrast, an average of only 1%
(SD = .02) of DE treatment tasks were marked by these behaviors. Similarly, an average
of 6% (SD = .05) of treatment tasks were re-completed by participants in the PE
condition when they were unable to complete subsequent tasks. This occurred in less
than 1% (SD = .05) of DE tasks.
Nonetheless, during the one-week follow-up session, 91.6% of participants who
received PE (all but one participant) reported their anxiety in the presence of the animal
had reduced by at least one third from the baseline assessment. This treatment response
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rate is similar to numbers reported in other studies of PE (85-90%; Ost, 1989; Ost,
Brandberg, et al., 1997).

Between-Session Changes
Behavioral Avoidance
A mixed model ANOVA was conducted to compare changes in the first
Behavioral Avoidance Test (BAT-1) scores between groups across three time periods
(Pre-Treatment, Post-Treatment, and One-Week Follow-up). There was no significant
interaction between treatment and time (Wilks' Lambda = .93, F (2, 21) = .745,/? = .487),
but there was a substantial main effect for time (Wilks' Lambda = .084, F (2, 21) = 115,/?
= .0005, d = 6.60), with both groups showing an increase in approach behaviors over
time. The main effect comparing the two treatments was not significant, however (F (1,
22) = .059,/? = .81), suggesting no difference in the efficacy of the interventions on this
measure. Due to scheduling difficulties and changes in contact information, only five
participants receiving PE and two participants receiving DE were able to be assessed
three months after the treatment session. Their results are included in the table below.

Table 1. Between-session changes in BAT-1 scores
Prolonged Exposure
Time period
Pre-Treatment
Post-Treatment
1 Week Follow-up
3 Month Follow-up

N
12
12
12
5

Mean
3.75
9
8.6
8.2

Dosed Exposure
SD
1.5
0
1.1
1.6
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N
12
12
12
2

Mean
3.75
9
9
9

SD
1.7
0
0
0

Figure 1. Between-session changes in BAT-1 scores
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The second Behavioral Avoidance Test (BAT-2) required the participant to hold
the previously feared animal in his or her hands for as long as he or she felt comfortable
(up to two minutes). Because four participants in the PE condition dropped out of
treatment before Task #17, they did not complete the BAT-2. Of the participants who did
complete the treatment, there were no significant differences found regarding how long
they were able to hold the animal immediately following the treatment or during the oneweek follow-up assessment (F (1, 17) = .7169jp = .409.

Table 2. Between-session changes in BAT-2 scores
Prolonged Exposure

Time period
Post-Treatment
1 Week Follow-up
3 Month Follow-up

N
8
8
5

Mean (s)
120
120
108
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Dosed Exposure

SD
0
0
24

N
12
12
2

Mean (s)
120
114
120

SD
0
20
0

Subjective Measures
In addition, a series of mixed model ANOVAs were conducted to compare
changes in each participant's self-reported feelings of anxiety, danger, and control
following the BAT-1. There were significant main effects for time, with both treatments
producing substantial reductions in anxiety (Wilks' Lambda = .186, F(2, 21) = 46.06, p =
.0005, d = 4.18) and perceptions of threat (Wilks' Lambda = .272, F(2,21) = 28.11,/? =
.0005, d = 3.27), and both treatments increased participants' feelings of control over their
environment (Wilks' Lambda = .29, F(2, 21) = 25.1,p = .0005, d - 3.13). However, the
main effect comparing the two interventions was not significant for changes in anxiety (F
(1, 22) = 1.37,/? = .256), danger (F (1, 22) = .424, p = .521), or control (F (1, 22) = 2.06,
p = A65).

Figure 2. Between-session changes in subjective anxiety
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Figure 3. Between-session changes in feelings of danger
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Figure 4. Between-session changes in feelings of control
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Paper-and-Pencil Measures
Changes in phobic cognitions across the three time periods were measured using
the Animal Questionnaires and the Animal Fear Scales. Pre-treatment scores on the
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Snake Questionnaire were similar between treatment conditions, and they were also
similar to scores of other snake phobics reported by other researchers (M = 24.44, SD =
2.95; Fredrikson, 1983; see table below). Likewise, pre-treatment scores on the Spider
Questionnaire were similar between treatment conditions and similar to scores of other
spider phobics (M = 23.76, SD = 3.8; Fredrikson, 1983). Although scores on these
questionnaires did significantly change over time (Wilks' Lambda = .096, F(2, 21) =
98.95,/? = .0005, d = 6.14), there was not a significant difference in these changes
between the two treatment conditions (F (1, 22) = 1.65, p = .212).
The Snake and Spider Fears Scales demonstrated similar changes in phobic
cognitions from pretreatment to post-treatment (Wilks' Lambda = .108, F(2, 21) = 86.97,
p = .0005, d = 5.75). However, like the scores on the Animal Questionnaires, there were
no significant differences between groups on the Animal Fear Scales (F (1, 22) = .303, p
= .588).

Table 3. Between-session changes in phobia measures

PreTx

Post Tx

1 Week

Total
Reduction in
Symptoms

Prolonged Exposures
Snake Questionnaire
Snake Fears Scale

21.0(2.8)
46.5 (7.1)

7.3 (1.6)
14.0 (9.0)

9.8 (2.6)
15.7(8.8)

52%
66%

Spider Questionnaire
Spider Fears Scale

21.0(2.0)
43.3 (4.3)

11.3(5.0)
19.7(14.9)

11.5(5.0)
21.8(13.1)

46%
49%

Dosed Exposures
Snake Questionnaire
Snake Fears Scale

22.0 (3.1)
50.3(11.8)

8.0 (3.9)
13.3(11.5)

6.0 (0)
14.0(11.5)

61%
76%

Spider Questionnaire
Spider Fears Scale

18.9(3.9)
47.9 (4.8)

7.5 (3.6)
15.4(7.1)

7.9 (3.8)
10.8(5.1)

60%
77%
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Within-Session Changes
To examine the emotional and cognitive changes taking place during the
treatment, each participant was asked to rate his or her feelings of anxiety, danger,
control, and self-efficacy at the end of each exposure task, and a mixed model ANOVA
was used to test for differences between treatment conditions. This method of analysis
was also used to examine within-session differences in heart rate between the treatments.
Because only 54% of participants (7 PE participants; 6 DE participants) completed at
least one of the first three tasks, only Tasks 4-17 were analyzed with respect to in-session
changes.
Anxiety (SUDS)
There was no significant interaction between the two treatments over time on selfreports of anxiety (Wilks' Lambda = .518, F(13, 6) = .429, p = .905), and, although there
was a downward trend in anxiety across both treatments, there was not a significant main
effect for time (Wilks' Lambda = .15, F(13, 6) = 2.62,p = .122). There was a significant
difference between the two treatments, however, with the dosed exposure condition
incurring greater feelings of anxiety across time compared to prolonged exposures (F (1,
18) = 5.66, p = .029). The magnitude of this difference was large (d = 1.12).
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Figure 5. Within-session changes in subjective anxiety
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Other Self-Reported Data
A downward trend was observed in feelings of danger over time; however, there
was not a significant main effect for time (Wilks' Lambda = .162, F(13, 6) = 2.40,/? =
.145). Similarly, there were no main effects for time with respect to self-reported
feelings of control (Wilks' Lambda = .198, F(13, 6) = 1.87, p = .228) and self-efficacy
(Wilks' Lambda = .402, F(13, 6) = 1.87,/? = .734). In addition, no significant differences
were detected between treatments on feelings of danger (F (1, 18) = 2.79, p = .112),
control (F (1, 18) = .068, p = .797), and self-efficacy (F (1, 18) = 1.11,/? = .306).
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Figure 6. Within-session changes in feelings of danger
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Figure 7. Within-session changes in feelings of control
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Figure 8. Within-session changes in self-efficacy
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Heart Rate
There was no significant interaction between treatment and time with respect to
heart rate (Wilks' Lambda = .256, F(13, 5) = 1.18,/> = .488), and the main effect for time
was not significant (Wilks' Lambda = .284, F(13, 5) = .972, p = .559). However, while
the PE condition incurred less anxiety during the course of treatment, participants in this
group had substantially greater heart rates during the treatment than participants in the
DE group (F (1, 17) = .588,p = .027) with a large effect size (d = 1.18).
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Figure 9. Within-session changes in heart rate
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Treatment Acceptability
Safety Behaviors
Rates of safety behaviors differed substantially between treatment conditions. An
average of 35% of the tasks during the Prolonged Exposure treatment were marked by at
least one safety behavior, while participants in the Dosed Exposure group exhibited these
behaviors during only 7% of the tasks. Results of an independent samples t-test
confirmed that the difference in the amount of safety behaviors exhibited between the
two groups (PE: M = 4.8, SD = 2.9; DE: M = 1.1; SD = 1.4) was significant (t (15.6) =
3.83, p = .002), and the magnitude of the difference (mean difference = 3.75, 95% CI:
1.67 to 5.83) was large (d = 1.63).
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Behavioral Indices of Distress
Any occurrences of crying, watery eyes, and visible shaking were recorded by the
therapist as a behavioral index of distress. Although these indices were observed in 22%
of PE tasks (M = 3.2 per participant, SD = 2.9) versus 10% of DE tasks (M = 1.7, SD =
2.4), these differences were not significant (t(22) = \.32,p = .20). In addition to the three
behavioral indices of distress specifically measured, two unique indices of distress were
noted from participants in the PE condition, with one participant fainting during the
treatment (Task #6) and another screaming and temporarily leaving the room (Task #3).
DEVS
The Distress/Endorsement Validation Scales (DEVS) was used to assess
participants' satisfaction with treatment during the one-week follow-up assessment. The
mean ratings on the Distress subscale were 35.4 (SD = 10.6) for PE and 30.0 (SD = 8.8)
for DE. These ratings were similar to average ratings of treatment-related distress
reported by Devilly (2004) from patients receiving either CBT (32.50), EMDR (31.18),
or intensive counseling (30.31) for posttraumatic stress. The mean ratings on the
Endorsement subscale were 21.2 (SD = 3.6) for PE and 23.7 (SD = 3.6) for DE. These
ratings were similar to treatment satisfaction ratings from patients receiving intensive
counseling for posttraumatic stress (22.4). The two treatment conditions did not differ
significantly on either the Distress (t(22) = 1.31, p = .205) or the Endorsement (t(22) = 1.63,p = .117) subscales.
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Treatment Integrity
Independent assessors reviewed 50%) of the treatment sessions via digital video.
Results showed that, in 100%) of the cases viewed, the therapist administered the
intervention according to protocol, the tasks were presented in the correct sequence, and
no exercises were added to the treatment. In addition, each exposure trial in the DE
condition was timed by the assessors, and a very strong correlation was found between
the prescribed trial durations and the actual durations (r = .969, p < .0005). A further
analysis of treatment integrity was conducted by scoring individual exposure trial
durations as delivered 'correctly' or 'incorrectly.' Durations between 5 and 30 seconds in
length were allowed to vary by ±10 seconds and durations between 60 and 120 seconds
in length were allowed to vary by ±20 seconds. Based on these criteria, only 2.9% of
trial durations were administered differently from the prescribed duration, and it is
important to note that no trial lasted longer than 141 seconds. Thus, it can be concluded
that exposures in the DE condition were, indeed, delivered in brief "doses."
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CHAPTER VII
DISCUSSION
This study compared two one-session behavioral treatments for specific animal
phobias: a well-studied treatment that subjected clients to prolonged periods of exposure
to fearful stimuli ("prolonged exposures"), and an experimental treatment that utilized a
massed series of exposures lasting 5 to 120 seconds in length ("dosed exposures"). The
results showed that the prolonged exposure treatment was conducted accurately and with
fidelity, and the treatment gains produced were similar to those of other studies on this
intervention (cf. Zlomke & Davis, 2008).
Contrary to the widespread belief that continuous contact with feared stimuli is
necessary in the treatment of anxiety and that brief exposures could hinder the effects of
treatment or even exacerbate a client's anxiety, this study found that, under the right
circumstances, brief exposures could produce both statistically significant and clinically
meaningful results. Dosed exposure therapy performed equally well to prolonged
exposures at decreasing behavioral avoidance, feelings of anxiety, perceptions of threat,
and phobia-specific cognitions from pretreatment to post-treatment, and these gains were
maintained at one-week and three-month follow-ups. During these follow-up sessions,
participants from the two groups reported equal degrees of distress experienced during
treatment and equivalent ratings of satisfaction with treatment gains. In addition, while
the Dosed Exposure treatments required participants to spend less time in contact with
feared stimuli, these treatments produced higher rates of treatment completion, better
compliance from participants, and fewer safety behaviors, on average. Dosed exposures
were also less likely to produce elevations in heart rate from participants. Despite these
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findings, the Prolonged Exposure treatment carried two advantages over its counterpart.
Namely, it required less total session time to administer, and participants reported lower
within-session SUDS ratings, on average.
Evaluation of Hypotheses
Four hypotheses were proposed before this study commenced. Hypothesis #1
stated that dosed exposures would produce equivalent reductions in anxiety at posttreatment as prolonged exposures. This hypothesis was supported by the data.
Behavioral tests, verbal reports of subjective feelings of anxiety, danger, and control, and
standardized paper-and-pencil measures all showed that prolonged and dosed exposures
produced equal reductions in anxiety.
Hypothesis #2 stated that average total treatment time for dosed exposure therapy
would be within one hour of the average total treatment time for prolonged exposure
therapy. This hypothesis was only partially supported by the data. While the Dosed
Exposure treatment for spider phobia took 41 minutes longer than the Prolonged
Exposure treatment, Dosed Exposure for snake phobia took 76 minutes longer than
Prolonged Exposure. While participants receiving either of the Dosed Exposure
treatments received less time in contact with the feared animal, the numerous inter-trial
break periods outside of the room coupled with the time required to repeatedly move the
snake and spiders during each exposure trial led to longer total session times.
Hypothesis #3 stated that participants receiving dosed exposures would be less
likely to engage in safety behaviors during the session than participants receiving
prolonged exposures. This hypothesis was supported by the data, showing a statistically
significant difference between the two treatments with a large effect size.
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Hypothesis #4 stated that participants receiving dosed exposures would find
treatment less aversive than participants receiving prolonged exposures. This hypothesis
was not supported by the data. While participants in the Dosed Exposure group engaged
in fewer safety behaviors and had lower heart rates than participants in the Prolonged
Exposure group, there were no significant differences in behavioral indices of distress or
one-week follow-up ratings of treatment distress and treatment satisfaction. In addition,
participants in the Prolonged Exposure group reported lower ratings of subjective anxiety
during the treatment than participants receiving Dosed Exposure.
Limitations
In spite of the interesting findings of this study - many of which run contrary to
existing beliefs about therapy - this study did have some significant limitations.
Foremost was the relatively small size of the samples used. While some significant
differences were found between the two groups and the study used sample sizes similar to
those of other studies of animal phobia treatments (mean N = 12.8 across studies, as
reported by Zlomke & Davis, 2008), it is possible that a larger sample size may have
helped detect other differences between the treatments.
Another limitation is the lack of long-term follow-up data. Only 29%o of
participants were able to be contacted and scheduled for a three-month follow-up
assessment, and even longer follow-up data (1 year or more) may have supported a
widespread implementation of dosed exposure therapy. However, the objective of this
study was not to study the long term effectiveness of either of the treatments, but to
examine whether a massed series of brief exposure trials would hinder the process and
post-treatment outcomes of exposure therapy.
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A final limitation pertains to the high degree of structure used in the study. All
treatments were conducted in a small, windowless room with clear floor markers
designating where to stand, and outside the room was a small quiet area for inter-trial
break periods. Such settings are unlikely to be found in most outpatient clinics.
Moreover, both treatment protocols were highly regimented, allowing for no flexibility
on the part of the therapist. It is unlikely that moving forward three feet at a time makes
much of a difference from moving two or four feet, and it is unlikely that exposure trials
lasting no longer than 120 seconds are significantly different from those lasting 220
seconds. In outpatient settings, these two treatments may proceed differently. However,
such rigid measures were required to reduce confounding effects from the individual
therapist or the therapy setting and to promote isolation of the variables under
examination.
Implications
The results of this experiment along with some of the previously cited studies
suggest that the notion that uninterrupted exposures are crucial to the reduction of anxiety
needs to be abandoned. In the case of specific animal phobias, dosed exposures can
produce treatment gains that are not only clinically significant, but similar to those
achieved with the gold standard intervention. In addition, these treatments require less
total time in contact with conditioned fear stimuli, a finding that is antithetical to earlier
theories of fear extinction (e.g., Foa & Kozak, 1986). Further analyses are now
warranted to clarify why this approach works.
It is clear that uncontrolled escape behaviors will negatively impact treatment
(Powers et al., 2004). Therefore, some element of response prevention is required during

49

any exposure-based intervention, whether it be client-directed or therapist-directed.
Research also suggests that, in order for brief exposures to be effective, they must be
delivered multiple times in a massed fashion (versus one or two brief exposure trials
before quitting).
It is also possible that the facilitation of approach behaviors is a critical
component of exposure therapy (Rentz et al., 2003). While simple habituation models
suggest that mere contact with feared stimuli over time will reduce anxiety, neither
treatment employed in the current study allowed for passive participation from
individuals. Instead, both treatments required participants to engage in actions that were
in opposition to typical fear responses.
The high volume of approach trials required from participants in the DE group
may have contributed to the lower rates of dropout from this treatment. For example,
while one participant in the PE condition sailed through the first 11 treatment tasks, when
it came to placing her hands near the spider, she was steadfastly unwilling. This
participant spent more time in contact with the animal than participants in the DE group.
However, she had engaged in only 11 approach behaviors versus the 42 trials completed
by DE participants by that stage of treatment.
It is also likely that the very brief periods of time in contact with feared stimuli
affected the way the treatment was experienced. For example, during the last two tasks,
which required participants to hold the previously feared animal in their hands,
participants in the PE group were more likely to report feelings of exhaustion or remark
that they had earned their accomplishment. On the other hand, participants receiving DE
often reported feelings of confusion or stated, "I can't believe I'm doing this."
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Unfortunately, the hope that dosed exposures would offer a less aversive
alternative to prolonged exposures was not supported by the data, as participants in the
DE group had higher SUDS ratings, on average. However, this study demonstrates that
verbal reports of one's internal experiences are poor predictors of actual behaviors, as
there was no relation between SUDS scores and rates of treatment completion.
Summary
In conclusion, this study shows that, contrary to popular belief, brief exposure
trials can be effective in the treatment of anxiety, leading to reductions in behavioral
avoidance, feelings of anxiety, perceptions of threat, and phobia-specific cognitions that
are equivalent to a well-established treatment. Because the dosed exposure approach
produced fewer in-session safety behaviors and lower dropout rates, it may eventually
prove to be a viable alternative to traditional, prolonged exposures. However, more
research using this approach with a wider array of anxiety disorders is needed.
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CHAPTER VIII
HUMAN SUBJECTS PROTECTION
Prior to any screening, measurement, or treatment, each participant read and
signed an informed consent document (Appendix F) which described the procedures used
in the study, the time commitment required of participants, and the right of the participant
to withdraw from the study at anytime without prejudice or penalty. The document also
outlined the risks, benefits, and protections for participants in the study. In addition, the
informed consent document included the names and phone numbers of the principal
investigator, the student investigator, the Chair of the WMU Human Subjects
Institutional Review Board, and the Vice President of Research, and it informed the
participants that they could contact any of these individuals during or after the course of
the study should any questions or concerns about the study arise.
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ERN MICHIGAN UNIVERSITY
Human Subjects Institutional Review Board

Date: May 12, 2009
To:

Richard Spates, Principal Investigator
Richard Seim, Student Investigator for dissertation

From: Amy Naugle, Ph.D., Ci^airJ^f%^N£tU^^—^^
Re:

HSIRB Project Number: 09-04-03

This letter will serve as confirmation that your research project titled "One-Session
Treatments for Animal Phobias" has been approved under the full category of review by
the Human Subjects Institutional Review Board. The conditions and duration of this
approval are specified in the Policies of Western Michigan University. You may now
begin to implement the research as described in the application.
Please note that you may only conduct this research exactly in the form it was approved.
You must seek specific board approval for any changes in this project. You must also
seek reapproval if the project extends beyond the termination date noted below. In
addition if there are any unanticipated adverse reactions or unanticipated events
associated with the conduct of this research, you should immediately suspend the project
and contact the Chair of the HSIRB for consultation,
The Board wishes you success in the pursuit of your research goals.
Approval Termination:

April 15,2010

Waiwood Hall, Kalamazoo, Ml 49008-5456
PHONE: (269)387-8293 FAX: (269)387-8276
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ESTERN MICHIGAN UNIVERSITY
Institutional Animal Care and Use Committee

-entennial
1903.2003 Celebration

Date: March 24, 2010
To:

C Richard Spates, Principal Ixrf^tjjge^or

From: Robert Eversole, Chair
Re:

IACUC Protocol No. 10-02-02

Your protocol titled "Dosed Stimulus Therapy for Small Animal Phobias T has received
approval from the Institutional Animal Care and Use Committee, The conditions and
duration of this approval are specified in the Policies of Western Michigan University.
You may now begin to implement the research as described in the application.
The Board wishes you success in the pursuit of your research goals.
Approval Termination:

March 24,2011

WaJwood Hall, Kalamazoo. Ml 49008-5456
nm. (269) 387-8293 m (269)387-8276
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Recruitment Script
Principal Investigator:
Student Investigator:
Title of Study:

C. Richard Spates, Ph.D.
Richard W. Seim, M.A.
One-Session Treatments for Animal Phobias

•

Are you afraid of spiders? Are you afraid of snakes? If so, you are invited to participate
in a research study entitled "One-Session Treatments for Animal Phobias."

•

This study is being conducted by Dr. Richard Spates and Richard Seim from the WMU
Department of Psychology

•

There are two well-supported treatments for snake and spider phobias. This study will
directly compare the effects and benefits of these two treatments.

•

If you choose to participate in this study, you will be invited to attend one treatment
session which will take no longer than five hours to complete

•

You will also be asked to attend two 15 minute follow-up sessions

•

Risks involve experiencing emotional discomfort during the treatment and follow-up
sessions

•

One way in which you may benefit from participating in this study is to eliminate your
fear of snakes or spiders. Treatments of this type have been shown to be very effective at
eliminating the phobias of other individuals. Also, other people with small animal
phobias may benefit from the knowledge that is gained from your participation in this
research.
If you are interested in learning more about participating in this study, please contact the
researchers by phone at the contact information on the slips of paper I will hand out.
Thank you
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Appendix D - Snake Flyer
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ARE YOU

AFRAID OF
SNAKES?
The WMU Anxiety Disorders Lab is recruiting
individuals to participate in a study investigating
treatments for Snake Phobias.
This study asks individuals to participate in
one treatment session and two follow-up measurement sessions
If you are interested in learning more, please contact
Richard Seim at 269-387-4332
Sponsored by the WMUDept. of Psychology
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Appendix E - Spider Flyer
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ARE YOU

AFRAID OF
SPIDERS?
The WMU Anxiety Disorders Lab is recruiting
individuals to participate in a study investigating
treatments for Spider Phobias.
This study asks individuals to participate in
one treatment session and two follow-up measurement sessions
If you are interested in learning more, please contact
Richard Seim at 269-387-4332
Sponsored by the WMU Dept. of Psychology
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Appendix F - Informed Consent Form
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WESTERN MICHIGAN UNIVERSITY

H. S. I. R. B.
Approved for use for one year from this date:

APR 1 5 2009

i
Western Michigan University
Department of Psychology
Principal Investigator:
Student Investigator:
Title of Study:

C. Richard Spates, Ph.D.
Richard W. Seim, M.A.
One-Session Treatments for Animal Phobias

You have been invited to participate in a research project titled "One-Session Treatments for
Animal Phobias. This project will serve as Richard Seinf s dissertation for the requirements of
the Ph.D. degree. This consent document will explain the purpose of this study and will go over
all of the time commitments, the procedures used in the study, and the risks and benefits of
participating in this research project. Please read this consent form carefully and completely and
please ask any questions if you need more clarification.
What are we trying to find out in this study?
There are two well-supported treatments for snake and spider phobias. This study will directly
compare the effects and benefits of these two treatments.
Who can participate in this study?
Adults between the ages of 18 and 60 can participate in this study. Participants must have a
significant fear of either snakes or spiders. Individuals who have a history of heart problems and
individuals who have problems standing, walking, or moving quickly should not participate in
this study. Also, individuals who are under the influence of a substance or who have started
taking medication or have changed their dosages for a medication for a psychiatric condition
within the last 30 days should not participate in this study.
Where will this study take place?
This study will take place in the therapy rooms in the 2500 Suite of Wood Hall.
What is the time commitment for participating in this study?
This study will involve one treatment session, which will take no more than five hours to
complete. It will also involve two 15 minute follow-up sessions. These will occur one week and
three months after the treatment session.
What will you be asked to do if you choose to participate in this study?
If you choose to participate in this study, you will be asked to answer questions about your fear
of snakes or spiders and complete several questionnaires about the nature of your fear. You will
also be asked to complete a Behavioral Avoidance Test, which will consist of you attempting to
stand as close to a feared animal as you are comfortable with for a brief period. During the
treatment, the therapist will assist you in gradually approaching a feared animal. You will also
be regularly asked to rate you anxiety, your sense of danger, and your feelings of control during
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the treatment. After the treatment you will be asked to complete more questionnaires and to recomplete the Behavioral Avoidance Test. You will also be asked to attend two 15 minute
follow-up sessions after the treatment. During these sessions, you will be asked to complete
three questionnaires and to complete the Behavioral Avoidance Test again.
What information is being measured during the study?
Several measures of anxiety will be recorded during this study including your self-reported
feelings of anxiety, your responses on five questionnaires, and your heart rate. If you choose to
participate in this study, parts of the treatment session will be videotaped. These recordings will
be stored in a locked file cabinet in 2523 Wood Hall, and they will only be accessible to the
researchers. After five years, the video recordings will be destroyed.
What are the risks of participating in this study and how will these risks be minimized?
As in all research, there may be unforeseen risks to the participant. If an accidental injury
occurs, appropriate emergency measures will be taken; however, no compensation or treatment
will be made available to you except as otherwise specified in this consent form. One potential
risk of participation in this project is that you may be emotionally upset in the presence of the
feared animal (during the Behavioral Avoidance Test and treatment). However, Richard Seim
and the trained therapists involved in this project are prepared to terminate the treatment session
and provide crisis counseling if you become significantly upset. Furthermore, they are prepared
to make a referral if you need further counseling on this topic. You will be responsible for the
cost of therapy if you choose to pursue it. There is a small risk of being harmed by the animal.
If you receive a bite from the animal, the therapists will offer immediate first aid treatment and
refer you to emergency medical personnel for further evaluation. You will be responsible for
any medical costs from this evaluation.
What are the benefits of participating in this study?
One way in which you may benefit from participating in this study is to eliminate your fear of
snakes or spiders. Treatments of this type have been shown to be very effective at eliminating
the phobias of other individuals. Also, other people with small animal phobias may benefit from
the knowledge that is gained from your participation in this research.
Are there any costs associated with participating in this study?
There are no costs associated with participating in this study.
Is there any compensation for participating in this study?
No compensation will be given for participating in this study.
Who will have access to the information collected during this study?
All of the information collected from you is confidential. This means that your name will not
appear on any papers on which this information is recorded. The forms will all be coded, and
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Richard Seim will keep a separate master list with the names of participants and the
corresponding code numbers in a locked file cabinet. Once the data are collected and analyzed,
the master list will be destroyed. All other forms will be retained for at least three years in a
locked file cabinet in the WMU Anxiety Disorders Laboratory.
What if you want to stop participating in this study?
You can choose to stop participating in the study at anytime for any reason. You will not suffer
any prejudice or penalty by your decision to stop your participation. You will experience NO
consequences either academically or personally if you choose to withdraw from this study. The
investigator may also decide to stop your participation in the study without your consent.
Should you have any questions prior to or during the study, you can contact the primary
investigator, C. Richard Spates at 269-387-4329 or a crspates@aol.com. You may also contact
the Chair of the Human Subjects Institutional Review Board at 269-387-8293 or the Vice
President for Research at 269-387-8298 if questions arise during the course of the study.
This consent document has been approved for use for one year by the Human Subjects
Institutional Review Board (HSIRB) as indicated by the stamped date and signature of the board
chair in the upper right corner. Do not participate in this study if the stamped date is older than
one year.

I have read this informed consent document. The risks and benefits have been explained to me. I
agree to take part in this study.

Please Print Your Name

Please Sign Your Name

Date
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Appendix G - Exclusionary Criteria Form
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Can you answer 'yes5 to any of the following questions?

• Are you younger than 18-years-oid?
• Do you have a history of heart problems?
• Do you have troubles standing, walking, or moving quickly?
• Have you started taking a medication for a psychiatric condition within the past
30 days?
• Have you changed dosages of a medication for a psychiatric condition within
the past 30 days?
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Appendix H - Counseling Referral Sites
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Local Counseling and Therapy Centers

WMU Psychology Clinic
1000 Oakland Drive
3 rd Floor
Kalamazoo, MI 49008
#269-387-8302

Center for Counseling and Psychological Services
3109 Sangren Hall
Kalamazoo, MI 49008
#269-387-5105

University Counseling and Testing Center
2513 Faunce Student Services Building
Kalamazoo, MI 49008
#269-387-1850
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Appendix I - Participant Demographics Form
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Participant #

Please answer the following questions as best as you can.

Age:
Gender (circle one):

• Male

Background: • African American
• Hispanic/Latino

• Female

• Asian/Pacific Islander

• Caucasian/White

• Native American

• Other

What small animal fear are you seeking treatment for? (circle one)
Spiders

Snakes

How many times in your life have you encountered this animal outdoors?

How many times in your life have you encountered this animal indoors?

How long ago did you last encounter this animal in real life, such as in a cage, in a building,
or in the wild?

Have you had this fear for over 6 months? (circle one)

Yes

No

If yes, for how long?

Please indicate the main type of area you lived in during these ages in your life:
Suburban Area
Inner City Area
Rural Area
Small Town
or City Outskirts
or Downtown
or Countryside
.ges 1-5
•
•
•
•
.ges 6-10
•
•
•
•
.ges 11-15
•
•
•
•
ges 15-20
•
•
•
•
resent age
•
•
•
•
81

Please answer the following questions about common fears using this scale:
0 = none

1 = mild

2 = moderate

3 = significant

How great is your
fear? ( 0 4 )

Snakes

0

f

Rats

0

1

Spiders

0

Dogs

4 = severe
Does this fear prevent you from
doing things you w o u l d otherwise
do?

H o w m u c h do you
avoid this? (0-4)
3

4

Prevents

/

Dbestft Prevent

2

3

4

Prevents

/

Doesn t Prevent

1

2

3

4

Prevents

/

Doesrit Prevent

0

1

2

3

4

Prevents

/

Doesn t Prevent

4

0

1

2

3

4

~ Prevents

f

Bo^n^Prevent

3

4

0

1

2

3

4

Prevents

/

Doesn t Prevent

1 2

3

4

0

1

2

3

4

Prevertfe

/

Doesn't Prevent

0

1 2

3

4

0

1

2

3

4

Prevents

/

Doesn t Prevent

Heights

0

1 2

3

4

0

1

3

4

Prevents

/

Ooesfft Prevent

Crayons

0

1 2

3

4

0

1

3

4

Prevents

/

Doesn t Prevent

Seeing blood

0

1

3

4

0

1

3

4

Prevents

/

Doesn't Prevent

Getting an injection

0

1 2

3

4

0

1 2

3

4

Prevents

/

Doesn t Prevent

Dental exams

0

1 2

3

4

0

f

3

4

Prevents

/

Doesn't Prevent

Tight enclosed spaces

0

1 2

3

4

0

1

3

4

Prevents

/

Doesn t Prevent

Elevators

0

1 2

3

4

0

1

Prevents

/

Doesn'tPrevent

Vomiting

0

1 2

3

4

0

1

4

Prevents

/

Doesn t Prevent

Seeing someone vomit

0

1 2

3

4

0

4

Prevents 4- Doesn t Prevent

Public speaking

0

1 2

3

4

0

1

2

3

4

Prevents

/

Doesn t Prevent

Rrdmg m a car

0

1 2

3

4

0

1

2

3

4

Prevents

/

Doesn't Prevent

Air travel

0

1 2

3

4

0

1

2

3

4

Prevents

/

Doesn t Prevent

The dark

0

1 2

3

4

0

1

3

4

Prevents

/

Xteesaft Prevent

Bndges

0

1 2

3

4

0

1

3

4

Prevents

/

Doesn t Prevent

Deep water

0

1 2

3

4

0

1

^3

4

Prevents

/

Doesn't Prevent

Clowns

0

1 2

3

4

0

1

2

3

4

Prevents

/

Doesn t Prevent

Thunderstorms

£

2

3

4

0

1

2

3

4

Prevents

/

Doesn't Prevent

Choking on food

0

1 2

3

4

0

1

2

3

4

Prevents

/

Doesn't Prevent

Catching an illness

0

1 2

3

4"

0

f

3

4

Prevents

/

DaesaWreveni

Gaining weight

0

1 2

3

4

0

1

3

4

Prevents

/

Doesn't Prevent

Evtfsprnts

$ - 1 2 3 4

.0

1

S

4

Prevents

L Doesn't Prevent

Meeting new people

0

1 2

3

4

0

1

2

3

4

Prevents

/

Walkmg through crowds

0

1

3

4

0

1

2

3

4

Prevents

/ -Doesn't Prevent

3

4

0

1

2

3

4

0

1

1

2

3

4

0

0

1

2

3

4

o

r

3

Birds

0

1 2

Cockroaches

0

Flying insects

Cats

—

1

2

2

2

2

Z

2
2

2

2
2
2

$__ -4

2

3

1

2

2
2
2

2
2
2

^

:

Please rate your expected success for treatment on a 1 - 10 scale
(1 = little success,
10 = much success)
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Doesn't Prevent

Appendix J - Snake Fears Scale
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Participant #
Snake Fears Scale
Please place a mark (X) in the space corresponding to your level of severity for each item. Use the following
scale to evaluate each item:
0=
1=
2=
3=
4=

None
MUd
Moderate
Significant
Severe
0

1

2

3

1. Fear of being in a room with a snake when alone
2. Fear of being in a room with a snake when other people are present
3. Fear of seeing pictures or videos of a snake
4. Fear of touching a snake with my fingers
5. Fearofholdingasnakeinmy hands
6. Fear of angering orfrighteninga snake

j

7. Fear of a snake biting me
8. Fear of a snake getting loose and crawling underneath my clothes

,

9. Fear of a snake leaping towards me
10. Fear of a snake chasing me
11. Fear of a snake making a noise

._

12. Avoidance of places where I might see a snake
13. Avoidance of places where a snake might have been in the past
14. How much distress do you experience due to a fear of snakes?
15. How significantly does a fear of snakes interfere with or impair your life?.
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Appendix K - Spider Fears Scale
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Participant #

Spider Fears Scale
Please place a mark (X) in the space corresponding to your level of severity for each item. Use the following
scale to evaluate each item:
0=
1=
2=
3=
4=

None
Mild
Moderate
Significant
Severe

0

1

2

3

1. Fear of being in a room with a spider when alone
2. Fear of being in a room with a spider when other people are present
3. Fear of seeing pictures or videos of a spider
4. Fear of touching a spider with my

fingers

.__

5. Fear of holding a spider in my hands
6. Fear of angering orfrighteninga spider
7. Fear of a spider biting me
8. Fear of a spider getting loose and crawling underneath my clothes '_
9. Fear of a spider leaping towards me
10. Fear of a spider chasing me

\

11. Fear of a spider making a noise
12. Avoidance of places where I might see a spider
13. Avoidance of places where a spider might have been in the past
14. How much distress do you experience due to a fear of spiders?
15. How significantly does a fear of spiders interfere with or impair your life?.
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Appendix L - Snake Treatment Tasks
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Snake Treatment Tasks

Approaching the Cage (with 5,10,15, and 30 sec durations)
1. Standing 12' away from the cage
2. Standing 9' away from the cage
3. Standing 6' away from the cage
4. Standing 3' away from the cage
5. Standing in front of the cage
Touching the Cage (with 5,10,15, 30 and 60 sec durations)
6. Touching the outside of the cage
7. Touching the rim of the cage
8. Touching the inside wall of the cage

Approaching the Tub (with 5,10,15, and 30 sec durations)
9. Standing 3' away from the tub
10. Standing in front of the tub
11. Touching the therapist's hand while he touches the snake

Approaching the Animal (with 5,10,15, 30, and 60 sec durations)
12. Touching the snake
13. Petting the snake's back
Learning to Hold the Animal (with 5,10,15, 30, 60, and 120 sec durations)
14. Touching the snake's belly
15. Supporting the weight of the snake's belly
16. Holding the snake with the therapist nearby

Holding the Animal by Oneself (with one 120 sec duration)
17. Holding the snake with the therapist standing 9' away

*AII treatment tasks were the same for the PE treatment
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Appendix M - Spider Treatment Tasks
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Spider Treatment Tasks

Approaching the Cage (with 5,10,15, and 30 sec durations)
1. Standing 12' away from the cage
2. Standing 9' away from the cage
3. Standing 6' away from the cage
4. Standing 3' away from the cage
5. Standing in front of the cage
Touching the Cage (with 5,10,15, 30 and 60 sec durations)
6. Touching the outside of the cage
7. Touching the rim of the cage
8. Touching the inside wall of the cage

Approaching the Tub (with 5,10,15, and 30 sec durations)
9. Standing 3' away from the tub
10. Standing in front of the tub
11. Moving the spider with a card

Approaching the Animal (with 5,10,15, 30, and 60 sec durations)
12. Capturing the spider with the card and cup
13. Touching the therapist's hand while he moves the spider with his hand

Learning to Hold the Animal (with 5,10,15, 30, 60, and 120 sec durations)
14. Moving the spider with the participant's hand
15. Having the spider stand on the participant's palms
16. Holding the spider with the therapist nearby
Holding the Animal by Oneself (with one 120 sec duration)
17. Holding the spider with the therapist standing 9' away

*AII treatment tasks were the same for the PE treatment
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Appendix N - Severity VAS
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0

25

50

75

100

None

Mild

Moderate

High

The most possible

Appendix O - Mastery VAS
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0

50

100

Incapable

Somewhat Capable

Completely Capable

Appendix P - BAT Checklist
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Participant

Pre-Treatment
1
2
3
4
5
6
7

Informed Consent
Exclusionary Cntena
Demographics Form
ADIS-IV
Anxiety Battery
Phobia Battery
Attach Heart Rate Monitor

Pre-BAT
HR1

Anxiety

Danger

Control

HR2

A
>12ft

B
12ft

C
9ft

D
6ft

E
3ft

F
Oft

Touch
Outside

(V

(2)

9)

(5)

(6)

(7)

BAT-1

Anxiety

Danger

Control

W
HR

EyesWater

Cfose :
Eyes

96

Cover
Face

Cry

Turn :

Touch
Inside

Touch
Rim

m
Shake

(9)
Hoid
Self

Arms
Out

Move
Back

Ask
Help

ReAssure

Appendix Q - Sample Participant Monitoring Form
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DE Snake Protocol

Participants

Task # 1 - Standing 1 2 ' A w a y f r o m Cage (line B)
Pre Task
Efficacy

Anxiety

Danger

Control

Anxiety

Danger

Control

Anxiety

Danger

Control

HR

Efficacy

Cover
Face

Cry

Tum
Away

Shake

Hold Setf

HR

Start Time

Trials
5 sec
10 sec
15 sec
30 sec

Post Task
Stop Time

Eyes
Water

Close
Eyes

Arms Oat

Move
Back

. A s k Help

ReAssure

Move
Back

Ask Help

ReAssure

Task # 2 - Standing 9 ' Away from Cage (line C)
Pre Task
Efficacy

Anxiety

Danger

Control

Anxiety

Danger

Control

Anxiety

Danger

Control

HR

Cover
Face

Cry

Turn
Away

Shake

HR

|

Start Time

Trials
5 sec
10 sec
15 sec
30 sec

Post Task
Stop Time

Eyes
Wafer

Close
Eyes
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Efficacy

BolriSeif • Arms Out ;
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